Trial Profile
An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Expanded access; Registrational
- Acronyms BALLET
- Sponsors Novartis
- 29 Jun 2016 Results published in the Annals of Oncology
- 12 Dec 2015 Sub group analysis results (n=919) presented at the 38th Annual San Antonio Breast Cancer Symposium
- 15 Aug 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.